AKTS – aktis oncology, inc. - common stock (US:AMEX)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

AKTS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/3

07:28 am

akts

Rating for AKTS

Medium Report

Rating for AKTS

Report

2/3

07:25 am

akts

Rating for AKTS

Medium Report

Rating for AKTS

Report

2/3

07:00 am

akts

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.

Medium Report

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.

Report

2/3

07:00 am

akts

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.

Medium Report

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.

Report

2/3

07:00 am

akts

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.

Medium Report

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.